Deals
HeartWare Rises as Study Sparks Talk of Acquisition
This article is for subscribers only.
HeartWare International Inc. had a record gain in Nasdaq trading after its implantable pump extended the lives of heart-failure patients in a study. Potential competitor Thoratec Corp. fell.
HeartWare, based in Framingham, Massachusetts, rose $13.92, or 19 percent, to $86.18 at 4 p.m. New York time in Nasdaq Stock Market composite trading, the biggest single-day jump since shares began trading in February 2009. The shares have more than doubled in the past 12 months. Thoratec fell $6.21, or 20 percent, to $24.74 for its biggest decline in almost five years.